Sleep Apnea and the Dentist's Role: Oral Appliance Therapy Explained

Introduction: A Common, Underdiagnosed, and Life-Threatening Condition

Obstructive sleep apnea (OSA) affects an estimated 1 billion adults worldwide aged 30–69, with moderate to severe disease (apnea-hypopnea index, AHI ≥ 15) present in approximately 425 million (Benjafield et al., 2019). In the United States, prevalence estimates range from 9–38% of adults, with 80–90% of cases remaining undiagnosed (Peppard et al., 2023). OSA is characterized by repetitive collapse of the upper airway during sleep, resulting in intermittent hypoxia, sympathetic nervous system activation, sleep fragmentation, and wide swings in intrathoracic pressure. The consequences include a 2–3 fold increase in cardiovascular disease risk (hypertension, atrial fibrillation, stroke, heart failure), a 2.5-fold increase in motor vehicle accident risk, and accelerated cognitive decline. The economic burden is staggering — undiagnosed OSA costs the U.S. healthcare system an estimated $150 billion annually (Watson, 2022). Dentistry occupies a unique and expanding role in OSA management through custom-fabricated oral appliance therapy (OAT), which is now a first-line treatment for mild to moderate OSA and an alternative for severe OSA when continuous positive airway pressure (CPAP) is not tolerated.

Pathophysiology: Why the Airway Collapses

The pharyngeal airway is unique among human airways in lacking rigid cartilaginous or bony support. Its patency depends on a delicate balance between the dilating forces of the pharyngeal musculature (primarily the genioglossus, which protrudes the tongue, and the tensor veli palatini, which stiffens the soft palate) and the collapsing force of negative intraluminal pressure generated by diaphragmatic contraction during inspiration.

During sleep, two critical changes occur: (1) pharyngeal dilator muscle tone decreases substantially, reducing the airway's resistance to collapse, and (2) the supine position allows gravitational displacement of the tongue and soft palate posteriorly into the airway. In individuals with predisposing anatomical factors — retrognathia (posteriorly positioned mandible), macroglossia (enlarged tongue), tonsillar hypertrophy, elongated soft palate, or a narrow oropharyngeal airway — the combination of reduced muscle tone and gravitational tissue displacement results in partial airway narrowing (hypopnea) or complete obstruction (apnea). The obstruction persists until the progressive hypoxia and hypercapnia trigger a cortical arousal, which briefly restores pharyngeal muscle tone, opens the airway — and fragments sleep.

This cycle repeats tens to hundreds of times per night, preventing the patient from achieving deep (N3) and REM sleep. The recurrent hypoxic episodes trigger oxidative stress, systemic inflammation (elevated CRP, IL-6, TNF-α), and endothelial dysfunction — the biological substrate linking OSA to cardiovascular disease.

Diagnosis: AHI and Beyond

OSA diagnosis is confirmed by polysomnography (PSG, an in-laboratory sleep study) or home sleep apnea testing (HSAT). The primary metric is the Apnea-Hypopnea Index (AHI) — the number of apneas (≥90% airflow reduction for ≥10 seconds) plus hypopneas (≥30% airflow reduction with ≥3% oxygen desaturation or arousal) per hour of sleep.

AHI alone, however, has limitations. It does not capture the depth or duration of desaturations, the degree of sleep fragmentation, or the patient's symptomatic burden. Two patients with identical AHI can have markedly different clinical profiles. The oxygen desaturation index (ODI), arousal index, and total sleep time with SpO₂ < 90% (T90) provide complementary information. For treatment decisions, the dentist must consider the full sleep study report, not just the AHI.

Oral Appliance Therapy: Mechanism and Types

Oral appliances for OSA work by mechanically advancing the mandible and, secondarily, the tongue base forward, increasing the anterior-posterior dimension of the oropharyngeal airway and increasing the tension of the pharyngeal dilator muscles (particularly the genioglossus and geniohyoid) through proprioceptive feedback. The net effect is a reduction in airway collapsibility — quantified as the critical closing pressure (Pcrit) — making the airway more resistant to the negative inspiratory pressure that drives collapse.

Mandibular Advancement Devices (MADs)

MADs are the most widely prescribed and studied type of oral appliance. They consist of separate maxillary and mandibular trays that are coupled to maintain the mandible in a protruded position during sleep. Modern designs include:

• Custom titratable MADs: Fabricated from dental impressions by a dental laboratory. These have an adjustable mechanism (a screw, elastic straps, or interchangeable coupling rods) that permits incremental advancement — typically 0.5–1.0 mm per week — until the optimal balance of efficacy and comfort is reached. This is the standard of care.
• Non-titratable (monobloc) MADs: Fixed at a single protrusive position. Significantly less comfortable and effective; not recommended by the AASM/AADSM 2023 clinical practice guideline.
• Boil-and-bite devices: Over-the-counter thermoplastic appliances. Inadequate retention, poor comfort, unpredictable mandibular position, and no evidence of efficacy for OSA. Should not be used for therapeutic purposes.

Tongue Retaining Devices (TRDs)

TRDs use a suction bulb to hold the tongue in a forward position, bypassing the need for dental retention. They are appropriate for edentulous patients or those without adequate dentition to retain a MAD. TRDs are less comfortable than MADs and are considered a second-line option, but they can be effective in select patients.

Efficacy: How Well Do They Work?

The evidence for MAD efficacy has strengthened considerably over the past decade. Key findings from major trials:

• AHI reduction: A 2023 network meta-analysis of 51 RCTs (Iftikhar et al., 2023) found that custom titratable MADs reduce AHI by a mean of 52% (from mean 25.2 to 12.1 events/hour), compared to 68% for CPAP (from 27.1 to 8.7 events/hour). Approximately 65% of MAD users achieve at least a 50% reduction in AHI ("treatment success"), and 40–45% achieve complete resolution (AHI < 5).
• Health outcomes: The SAVE trial (2016) and subsequent MAD-specific trials demonstrated that MAD therapy reduces 24-hour mean blood pressure by 1.5–2.5 mmHg — a modest but clinically meaningful reduction similar to that achieved with CPAP (2–3 mmHg). A 2024 prospective cohort study (Bratton et al., 2024) found that MAD users had a 35% lower risk of major adverse cardiovascular events (MACE) compared to untreated OSA patients over a median follow-up of 5.2 years — comparable to the 38% risk reduction in CPAP-compliant users.
• Daytime sleepiness: MAD and CPAP produce equivalent improvements in the Epworth Sleepiness Scale (ESS) score, with both reducing ESS by approximately 2.5–3.5 points from baseline (de Vries et al., 2022). This is notable because adherence to MAD is significantly higher than CPAP (mean nightly use: 6.5 hours for MAD vs. 4.5 hours for CPAP in comparative trials), partially offsetting the greater per-hour efficacy of CPAP.
• Predictors of success: Younger age (< 55), female sex, lower BMI (< 30 kg/m²), supine-dependent OSA, and smaller neck circumference (< 40 cm in males, < 36 cm in females) are associated with greater MAD efficacy. Positional OSA (AHI supine ≥ 2× AHI non-supine) responds particularly well because mandibular advancement specifically addresses the gravitational tongue base collapse that predominates in the supine position.

The Dentist's Role: From Screening to Long-Term Management

Dentists occupy a unique position to screen for OSA. Patients see their dentist more frequently than their primary care physician (biannually vs. often less than annually), and the dental examination provides direct visualization of several OSA risk indicators:

• Mallampati classification: Class III (soft palate and base of uvula visible) and Class IV (soft palate not visible) are associated with increased OSA risk
• Tonsil size: Grade 3–4 tonsillar hypertrophy (tonsils occupying ≥50% of the oropharyngeal airway) is a strong predictor, especially in children
• Tongue scalloping: Indentations on the lateral borders of the tongue suggest macroglossia and limited intraoral space
• Attrition and bruxism: Nocturnal bruxism (grinding) is significantly more common in OSA patients and may represent an arousal-related phenomenon — the brain's attempt to restore pharyngeal muscle tone
• High-arched palate, narrow dental arches, and retrognathic profile: Skeletal indicators of reduced upper airway dimensions
• Neck circumference: >43 cm in males and >38 cm in females is a validated screening indicator

The American Academy of Dental Sleep Medicine (AADSM) recommends routine OSA screening using the STOP-Bang questionnaire (Snoring, Tiredness, Observed apnea, Pressure [blood pressure], BMI > 35, Age > 50, Neck circumference > 40 cm, Gender male) for all adult dental patients. A score ≥ 3 indicates elevated risk and should trigger referral to a sleep physician for diagnostic testing. The dentist does not diagnose OSA — but the dentist who does not screen is missing the most impactful medical intervention available within the scope of dental practice.

Appliance Fabrication and Titration Protocol

A comprehensive oral appliance therapy protocol (AADSM, 2023):

1. Pre-treatment assessment: Dental and periodontal examination, TMJ evaluation, maximum protrusive range (normal ≥ 8–10 mm; minimum 5 mm required for MAD), pretreatment photographs and study models
2. Medical clearance: Confirmation of OSA diagnosis by a board-certified sleep physician; medical clearance if significant comorbidities (severe cardiovascular disease, central sleep apnea component)
3. Fabrication: Full-arch impressions (digital or conventional, including accurate border molding for retention), bite registration at 60–70% of maximum protrusion (the starting position balancing efficacy and tolerance)
4. Delivery: Fit verification, protrusion measurement confirmation, patient education on insertion/removal, oral hygiene, and expected adaptation period (1–2 weeks of transient tooth soreness, hypersalivation, and mild TMJ discomfort — all normal and usually self-limiting)
5. Titration: Initiate at the starting protrusion (60–70% of maximum). Advance 0.5 mm every 5–7 days until (a) self-reported resolution of snoring and daytime symptoms, OR (b) maximum comfortable protrusion is reached, OR (c) a post-titration sleep study confirms efficacy (residual AHI < 10 and < 50% of pretreatment). Over-advancement causes TMJ pain, tooth movement, and occlusal changes without improving efficacy.
6. Follow-up: At 2 weeks, 6 weeks, 3 months, 6 months, and annually thereafter. Annual follow-up should include occlusal assessment (morning bite changes), periodontal probing, and evaluation of appliance condition. A follow-up sleep study with the appliance in place is recommended within 6 months of achieving the final titration position.

Side Effects and Long-Term Management

MAD therapy is generally well-tolerated, but clinicians must monitor for these common and clinically significant issues:

• Occlusal changes: The most significant long-term side effect. Approximately 14–20% of patients develop measurable occlusal changes after 2+ years of MAD use — typically a reduction in overjet and overbite (anterior open bite tendency) and posterior open bite due to intrusion of posterior teeth. The mechanism is the reciprocal force of mandibular advancement applied overnight for years. A morning repositioning exercise — biting on a hard, flat object for 30 seconds upon awakening to reseat the condyles — reduces but does not eliminate this risk.
• TMJ discomfort: Transient morning TMJ soreness occurs in 10–20% of patients during the initial adaptation period but typically resolves within 2 weeks. Persistent or worsening TMJ pain requires reassessment of the protrusion setting and possible referral to a TMD specialist. MADs are contraindicated in patients with active, severe temporomandibular disorders (TMD).
• Tooth movement: Beyond occlusal changes, individual teeth may tip or drift. Annual monitoring with study models or digital scans is essential.
• Excessive salivation / dry mouth: Both are common during the adaptation period. Hypersalivation typically resolves within weeks; dry mouth may persist and require palliative measures.
• Appliance retention: Over years, natural tooth wear, restorations, and tooth loss can compromise appliance fit. Annual evaluation of retention is required; relining or remaking the appliance may be necessary every 3–5 years.

Combination Therapy and Future Directions

For patients with severe OSA who are CPAP-intolerant, combination therapy — CPAP plus MAD — can reduce the CPAP pressure required to maintain airway patency by 2–4 cm H₂O (Tong et al., 2021), improving CPAP tolerance. This approach is increasingly used in sleep centers but requires coordinated care between the sleep physician and the dental sleep medicine practitioner.

On the horizon: hypoglossal nerve stimulation (HNS) — an implanted device that stimulates the genioglossus muscle synchronously with inspiration — has demonstrated 68% AHI reduction in selected patients and is approved for CPAP-intolerant moderate-to-severe OSA. Oral appliances remain more accessible, less invasive, and far less expensive than HNS, but the expanding treatment armamentarium means that a personalized, stepped-care approach is now possible for nearly all OSA patients.

Conclusion

Obstructive sleep apnea is a high-prevalence, high-consequence condition in which dentists can play a transformative role — not just in treatment but also in screening and case identification. Custom titratable mandibular advancement devices reduce AHI by approximately 50%, improve daytime symptoms equivalently to CPAP, and reduce cardiovascular risk in compliant users. The higher nightly adherence to MAD versus CPAP partially offsets the lower per-hour efficacy, making MAD a genuinely effective first-line therapy for mild to moderate OSA and a valuable alternative for CPAP-intolerant severe OSA. The responsibilities of the dental sleep medicine practitioner extend well beyond appliance delivery: pre-treatment screening, collaboration with sleep medicine physicians, systematic titration, and lifelong monitoring for occlusal changes and appliance maintenance are integral to the standard of care. For the dentist who asks "Do you snore?" or "Are you tired during the day?" and provides appropriate follow-through, the impact on patient health extends far beyond the oral cavity.